Changes in costs and effects after the implementation of disease management programs in the Netherlands: variability and determinants

Cost Effectiveness and Resource Allocation

Maureen PMH Rutten-van Mölken¹  Anna P Nieboer¹  Jane Murray Cramm¹  Apostolos Tsiachristas¹ 

[1] Department of Health Policy and Management, Erasmus University Rotterdam, P.O. Box 1738, Rotterdam, 3000 DR, The Netherlands

关键词: COPD;    Diabetes;    Cardiovascular disease;    Coordinated care;    Effectiveness;    Costs;   

Others  :  1109995
DOI  :  10.1186/1478-7547-12-17

 received in 2014-02-19, accepted in 2014-07-22,  发布年份 2014

【 摘 要 】

Objectives

The aim of the study was to investigate the changes in costs and outcomes after the implementation of various disease management programs (DMPs), to identify their potential determinants, and to compare the costs and outcomes of different DMPs.

Methods

We investigated the 1-year changes in costs and effects of 1,322 patients in 16 DMPs for cardiovascular risk (CVR), chronic obstructive pulmonary disease (COPD), and diabetes mellitus (DMII) in the Netherlands. We also explored the within-DMP predictors of these changes. Finally, a cost-utility analysis was performed from the healthcare and societal perspective comparing the most and the least effective DMP within each disease category.

Results

This study showed wide variation in development and implementation costs between DMPs (range:€16;€1,709) and highlighted the importance of economies of scale. Changes in health care utilization costs were not statistically significant. DMPs were associated with improvements in integration of CVR care (0.10 PACIC units), physical activity (+0.34 week-days) and smoking cessation (8% less smokers) in all diseases. Since an increase in physical activity and in self-efficacy were predictive of an improvement in quality-of-life, DMPs that aim to improve these are more likely to be effective. When comparing the most with the least effective DMP in a disease category, the vast majority of bootstrap replications (range:73%;97) pointed to cost savings, except for COPD (21%). QALY gains were small (range:0.003;+0.013) and surrounded by great uncertainty.

Conclusions

After one year we have found indications of improvements in level of integrated care for CVR patients and lifestyle indicators for all diseases, but in none of the diseases we have found indications of cost savings due to DMPs. However, it is likely that it takes more time before the improvements in care lead to reductions in complications and hospitalizations.

【 授权许可】

   
2014 Tsiachristas et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Nolte E, Mckee M: Making It Happen. In Caring For People With Chronic Conditions. Edited by Nolte E, Mckee M. Berkshire, England: Open University Press; 2008.
• [2]Cramm JM, Nieboer AP: In the Netherlands, rich interaction among professionals conducting disease management led to better chronic care. Health Aff (Millwood) 2012, 31(11):2493-2500.
• [3]Conklin A, Nolte E, Vrijhoef H: Approaches to chronic disease management evaluation in use in Europe: a review of current methods and performance measures. Int J Technol Assess Health Care 2013, 29(1):61-70.
• [4]Knai C, Nolte E, Brunn M, Elissen A, Conklin A, Pedersen JP, Brereton L, Erler A, Frolich A, Flamm M, Fullerton B, Jacobsen R, Krohn R, Saz-Parkinson Z, Vrijhoef B, Chevreul K, Durand-Zaleski I, Farsi F, Sarria-Santamera A, Soennichsen A: Reported barriers to evaluation in chronic care: experiences in six European countries. Health Policy 2013, 110(2–3):220-228.
• [5]Tsiachristas A, Hipple-Walters B, Lemmens KM, Nieboer AP, Rutten-van Molken MP: Towards integrated care for chronic conditions: Dutch policy developments to overcome the (financial) barriers. Health Policy 2011, 101(2):122-132.
• [6]de Bakker D, Raams R, Schut E, Vrijhoef B, de Wildt JE: Eindrapport van de Evaluatiecommissie Integrale Bekostiging Integrale bekostiging van zorg: Werk in uitvoering. The Hague: ZonMw; 2012.
• [7]Barnett K, Mercer SW, Norbury M, Watt G, Wyke S, Guthrie B: Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study. Lancet 2012, 380(9836):37-43.
• [8]Lemmens KM, Rutten-Van Molken MP, Cramm JM, Huijsman R, Bal RA, Nieboer AP: Evaluation of a large scale implementation of disease management programmes in various Dutch regions: a study protocol. BMC Health Serv Res 2011, 11:6.
• [9]Tsiachristas A, Cramm JM, Nieboer A, Rutten-van Molken M: Broader economic evaluation of disease management programs using multi-criteria decision analysis. Int J Technol Assess Health Care 2013, 29(3):301-308.
• [10]Cramm JM, Tsiachristas A, Walters BH, Adams SA, Bal R, Huijsman R, van Mölken MPMH R, Nieboer AP: The management of cardiovascular disease in the Netherlands: analysis of different programmes. Int J Integr Care 2013., 13Jul–Sep
• [11]Glasgow RE, Wagner EH, Schaefer J, Mahoney LD, Reid RJ, Greene SM: Development and validation of the Patient Assessment of Chronic Illness Care (PACIC). Med Care 2005, 43(5):436-444.
• [12]Cramm JM, Strating MM, de Vreede PL, Steverink N, Nieboer AP: Validation of the self-management ability scale (SMAS) and development and validation of a shorter scale (SMAS-S) among older patients shortly after hospitalisation. Health Qual Life Outcomes 2012, 10:9-7525. -10-9
• [13]Lamers LM, McDonnell J, Stalmeier PF, Krabbe PF, Busschbach JJ: The Dutch tariff: results and arguments for an effective design for national EQ-5D valuation studies. Health Econ 2006, 15(10):1121-1132.
• [14]Johns B, Baltussen R, Hutubessy R: Programme costs in the economic evaluation of health interventions. Cost Eff Resour Alloc 2003, 1(1):1.
• [15]Koopmanschap MA, Rutten FF, van Ineveld BM, van Roijen L: The friction cost method for measuring indirect costs of disease. J Health Econ 1995, 14(2):171-189.
• [16]Tan SS, Bouwmans CA, Rutten FF, Hakkaart-van Roijen L: Update of the Dutch manual for costing in economic evaluations. Int J Technol Assess Health Care 2012, 28(2):152-158.
• [17]Stuart EA: Matching methods for causal inference: a review and a look forward. Stat Sci 2010, 25(1):1-21.
• [18]Charlson ME, Charlson RE, Peterson JC, Marinopoulos SS, Briggs WM, Hollenberg JP: The Charlson comorbidity index is adapted to predict costs of chronic disease in primary care patients. J Clin Epidemiol 2008, 61(12):1234-1240.
• [19]Noel PH, Parchman ML, Palmer RF, Romero RL, Leykum LK, Lanham HJ, Zeber JE, Bowers KW: Alignment of patient and primary care practice member perspectives of chronic illness care: a cross-sectional analysis. BMC Fam Pract 2014, 15:57-2296. -15-57
• [20]Cramm JM, Nieboer AP: High-quality chronic care delivery improves experiences of chronically ill patients receiving care. Int J Qual Health Care 2013, 25(6):689-695.
• [21]Hoogendoorn M, Feenstra TL, Hoogenveen RT, Rutten-van Molken MP: Long-term effectiveness and cost-effectiveness of smoking cessation interventions in patients with COPD. Thorax 2010, 65(8):711-718.
• [22]de Korte-de Boer D, Kotz D, Viechtbauer W, van Haren E, Grommen D, de Munter M, Coenen H, Gorgels AP, van Schayck OC: Effect of smoke-free legislation on the incidence of sudden circulatory arrest in the Netherlands. Heart 2012, 98:995-999. Heart 2012, 98(22):1680-2012-302752. Epub 2012 Aug 23
• [23]Spencer S, Calverley PM, Sherwood Burge P, Jones PW, ISOLDE Study Group: Inhaled steroids in obstructive lung disease: health status deterioration in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001, 163(1):122-128.
• [24]Cunningham AJ, Lockwood GA, Cunningham JA: A relationship between perceived self-efficacy and quality of life in cancer patients. Patient Educ Couns 1991, 17(1):71-78.
• [25]Middleton J, Tran Y, Craig A: Relationship between quality of life and self-efficacy in persons with spinal cord injuries. Arch Phys Med Rehabil 2007, 88(12):1643-1648.
• [26]Coleman K, Austin BT, Brach C, Wagner EH: Evidence on the chronic care model in the new millennium. Health Aff (Millwood) 2009, 28(1):75-85.
• [27]Verstappen WH, van Merode F, Grimshaw J, Dubois WI, Grol RP, van der Weijden T: Comparing cost effects of two quality strategies to improve test ordering in primary care: a randomized trial. Int J Qual Health Care 2004, 16(5):391-398.
• [28]Roland M, Paddison C: Better management of patients with multimorbidity. BMJ 2013, 346:f2510.
• [29]Goodwin N, Dixon A, Anderson G, Wodchis W: Providing integrated care for older people with complex needs: lessons from seven international case studies. London, UK: The King’s Fund; 2014.
• [30]Pomp M: Populatiebekostiging: panacee, hype of verkapt kartel? Nederlandse Zorgautoriteit 2013, 2013–1:1-61.
• [31]Cramm JM, Adams SA, Walters BH, Tsiachristas A, Bal R, Huijsman R, Rutten-Van Molken MP, Nieboer AP: The role of disease management programs in the health behavior of chronically ill patients. Patient Educ Couns 2014, 95(1):137-142.
• [32]Cramm JM, Rutten-Van Molken MP, Nieboer AP: The potential for integrated care programmes to improve quality of care as assessed by patients with COPD: early results from a real-world implementation study in The Netherlands. Int J Integr Care 2012, 12:e191. -Sep
• [33]Conklin A, Nolte E: Disease management evaluation: a comprehensive review of current state of the art. RAND 2010, 1-97.
• [34]Tinkelman D, Wilson S: Regression to the mean: a limited issue in disease management programs for chronic obstructive pulmonary disease. Dis Manag 2008, 11(2):103-110.